Severe spruelike enteropathy associated with olmesartan

Alberto Rubio Tapia, Margot L. Herman, Jonas F. Ludvigsson, Darlene G. Kelly, Thomas F. Mangan, Tsung Teh Wu, Joseph A. Murray

Research output: Contribution to journalArticle

236 Scopus citations

Abstract

Objective: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy. Patients and Methods: All 22 patients included in this report were seen at Mayo Clinic in Rochester, Minnesota, between August 1, 2008, and August 1, 2011, for evaluation of unexplained chronic diarrhea and enteropathy while taking olmesartan. Celiac disease was ruled out in all cases. To be included in the study, the patients also had to have clinical improvement after suspension of olmesartan. Results: The 22 patients (13 women) had a median age of 69.5 years (range, 47-81 years). Most patients were taking 40 mg/d of olmesartan (range, 10-40 mg/d). The clinical presentation was of chronic diarrhea and weight loss (median, 18 kg; range, 2.5-57 kg), which required hospitalization in 14 patients (64%). Intestinal biopsies showed both villous atrophy and variable degrees of mucosal inflammation in 15 patients, and marked subepithelial collagen deposition (collagenous sprue) in 7. Tissue transglutaminase antibodies were not detected. A gluten-free diet was not helpful. Collagenous or lymphocytic gastritis was documented in 7 patients, and microscopic colitis was documented in 5 patients. Clinical response, with a mean weight gain of 12.2 kg, was demonstrated in all cases. Histologic recovery or improvement of the duodenum after discontinuation of olmesartan was confirmed in all 18 patients who underwent follow-up biopsies. Conclusion: Olmesartan may be associated with a severe form of spruelike enteropathy. Clinical response and histologic recovery are expected after suspension of the drug.

Original languageEnglish (US)
Pages (from-to)732-738
Number of pages7
JournalMayo Clinic proceedings
Volume87
Issue number8
DOIs
StatePublished - Aug 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Severe spruelike enteropathy associated with olmesartan'. Together they form a unique fingerprint.

  • Cite this

    Rubio Tapia, A., Herman, M. L., Ludvigsson, J. F., Kelly, D. G., Mangan, T. F., Wu, T. T., & Murray, J. A. (2012). Severe spruelike enteropathy associated with olmesartan. Mayo Clinic proceedings, 87(8), 732-738. https://doi.org/10.1016/j.mayocp.2012.06.003